CVRx to Present at the Piper Sandler 34th Annual Healthcare Conference

Rhea-AI Summary

CVRx, a medical device company focused on neuromodulation solutions for cardiovascular diseases, will participate in the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 8:00 am Eastern Time. The presentation will be available via a live audio webcast on the company’s investor relations page. CVRx’s primary product, the Barostim™ System, is the first FDA-approved medical technology using neuromodulation to alleviate heart failure symptoms. The device has received FDA Breakthrough Device designation and CE Mark approvals for heart failure and resistant hypertension.

MINNEAPOLIS, Nov. 16, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”),  a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022. The Company is scheduled to present at the conference at 8:00 am Eastern Time the same day via webcast.

A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com. A replay of the webcast will be archived on the website for approximately 90 days.

About CVRx, Inc.

CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com

Media Contact:
Erich Sandoval
Finn Partners
212-867-1762
erich.sandoval@finnpartners.com

FAQ

When is CVRx's presentation at the Piper Sandler Healthcare Conference?

CVRx is scheduled to present at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 8:00 am Eastern Time.

How can I watch the CVRx presentation online?

The CVRx presentation will be available via a live audio webcast on the company's investor relations page at ir.cvrx.com.

What is the Barostim System developed by CVRx?

The Barostim System is an implantable device approved by the FDA that uses neuromodulation to improve symptoms of heart failure.

What designations has the Barostim System received?

The Barostim System received FDA Breakthrough Device designation and is FDA-approved for heart failure treatment in the U.S., as well as CE Mark approval for heart failure and resistant hypertension in the European Economic Area.

Where can I find more information about CVRx?

More information about CVRx and the Barostim System can be found on their website at www.cvrx.com.